Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2025 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of Service
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to The Report
Biotech

HorizonDynamics

HorizonDynamics Raises $1B Growth to Transform Biotech

$1B Growth
Total Raised
Growth
Latest Round
2025
Founded
250-500
Employees
Washington, DC
Updated October 4, 2025
1 min read

Quick Facts

Valuation
$15B
Latest Round Size
$1B Growth
Latest Round Date
October 2025

HorizonDynamics Raises $1B Growth in Latest Funding Round

HorizonDynamics has successfully closed a $1B Growth funding round, marking a significant milestone in the company's growth trajectory. The round was led by Lightspeed Venture Partners, with participation from 500 Startups.

Company Overview

Founded in 2025 and headquartered in Washington, DC, HorizonDynamics has established itself in the Biotech space. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses

With a current valuation of $15B, the company has demonstrated strong market traction and investor confidence.

Investment Details

  • Amount Raised: $1B Growth
  • Valuation: $15B
  • Lead Investor: Lightspeed Venture Partners

Future Outlook

As HorizonDynamics moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.

Key Investors

Lightspeed Venture Partners
Venture Capital
Leading venture capital firm investing in technology companies
500 Startups
Venture Capital
Leading venture capital firm investing in technology companies

Topics

Venture Capital(911)Technology(815)Startup Funding(564)BiotechGrowth

About the Author

David Chen
David Chen
Technology investment researcher specializing in enterprise software and infrastructure deals at top-tier venture funds.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min readβ€’$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$250M